Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 24
2.
Vet J ; 265: 105552, 2020 Nov.
Article En | MEDLINE | ID: mdl-33129552

Amyloidosis in Siamese/Oriental cats is a lethal condition with variable age of clinical onset. There is no sex predisposition and clinical signs of disease usually become apparent by 1-7 years of age. In the terminal stages, the liver is enlarged and pale, and contains parenchymal hemorrhages. In the present study, pedigree data from 17 cats with clinical signs consistent with amyloidosis underwent genetic analysis. Necropsy and histopathological data were available for 10 of the 17 cats. Necropsy findings included pale, fragile and enlarged livers with capsular ruptures and parenchymal hemorrhages, and sanguineous effusions in the abdominal cavity. Congo red staining with birefringence confirmed systemic amyloidosis mostly involving the liver and thyroid gland. In four of the 10 cases, protein deposits were classified as amyloid A protein (AA-amyloid) by immunostaining. Pedigree data for all 17 affected cats indicated a familial trait. Animal threshold model analysis demonstrated that the heritability for amyloidosis was 0.56 ± 0.09 (standard error). Complex segregation analysis was used for statistical comparisons among models to determine environmental or sex dependent effects, and Mendelian, polygenic, or mixed Mendelian and polygenic inheritance patterns. A mixed model with a Mendelian and polygenic component provided the best fit to the data and thus was most likely. All other models of inheritance were rejected due to their insufficient ability to explain segregation of amyloidosis. In conclusion, we found evidence for a complex genetic basis for amyloidosis in Oriental shorthair cats.


Amyloidosis, Familial/veterinary , Cat Diseases/genetics , Chromosome Segregation/genetics , Pedigree , Amyloidosis, Familial/genetics , Amyloidosis, Familial/pathology , Animals , Cat Diseases/metabolism , Cat Diseases/pathology , Cats , Female , Liver/chemistry , Liver/pathology , Male , Serum Amyloid A Protein/analysis , Thyroid Gland/chemistry , Thyroid Gland/pathology
3.
Clin Exp Immunol ; 199(1): 97-108, 2020 01.
Article En | MEDLINE | ID: mdl-31509227

Kidney injury significantly increases overall mortality. Neutrophilic granulocytes (neutrophils) are the most abundant human blood leukocytes. They are characterized by a high turnover rate, chiefly controlled by granulocyte colony stimulating factor (G-CSF). The role of kidney injury and uremia in regulation of granulopoiesis has not been reported. Kidney transplantation, which inherently causes ischemia-reperfusion injury of the graft, elevated human neutrophil expression of the surface glycoprotein CD177. CD177 is among the most G-CSF-responsive neutrophil genes and reversibly increased on neutrophils of healthy donors who received recombinant G-CSF. In kidney graft recipients, a transient rise in neutrophil CD177 correlated with renal tubular epithelial G-CSF expression. In contrast, CD177 was unaltered in patients with chronic renal impairment and independent of renal replacement therapy. Under controlled conditions of experimental ischemia-reperfusion and unilateral ureteral obstruction injuries in mice, renal G-CSF mRNA and protein expression significantly increased and systemic neutrophilia developed. Human renal tubular epithelial cell G-CSF expression was promoted by hypoxia and proinflammatory cytokine interleukin 17A in vitro. Clinically, recipients of ABO blood group-incompatible kidney grafts developed a larger rise in neutrophil CD177. Their grafts are characterized by complement C4d deposition on the renal endothelium, even in the absence of rejection. Indeed, complement activation, but not hypoxia, induced primary human endothelial cell G-CSF expression. Our data demonstrate that kidney injury induces renal G-CSF expression and modulates granulopoiesis. They delineate differential G-CSF regulation in renal epithelium and endothelium. Altered granulopoiesis may contribute to the systemic impact of kidney injury.


Basigin/metabolism , Endothelium/metabolism , Gene Expression Regulation , Granulocyte Colony-Stimulating Factor/biosynthesis , Neutrophils/metabolism , Renal Insufficiency/metabolism , Thrombopoiesis , Animals , Basigin/immunology , Disease Models, Animal , Endothelium/immunology , Endothelium/pathology , Female , Granulocyte Colony-Stimulating Factor/immunology , Humans , Kidney Transplantation , Male , Mice , Neutrophils/immunology , Neutrophils/pathology , Renal Insufficiency/immunology , Renal Insufficiency/pathology , Renal Insufficiency/surgery , Reperfusion Injury/immunology , Reperfusion Injury/metabolism , Reperfusion Injury/pathology , Ureteral Obstruction/immunology , Ureteral Obstruction/metabolism , Ureteral Obstruction/pathology
5.
Sci Rep ; 9(1): 17718, 2019 11 27.
Article En | MEDLINE | ID: mdl-31776394

Hermansky-Pudlak Syndrome (HPS) is a rare disease caused by mutations in the genes coding for various HPS proteins. HPS proteins are part of multi-subunit complexes involved in the biogenesis of organelles from the lysosomal-endosomal-system. In humans, this syndrome is characterized by the presence of albinism, platelet dysfunction and pulmonary fibrosis. The renal component to the disease remains unstudied and untreated in patients with HPS. Here we demonstrate that in humans, HPS proteins have a high renal expression with active transcription of HPS1, 3, 4 and 5 in human podocyte cell culture, suggesting that impaired function of HPS proteins could directly impact renal function. Therefore, we developed a zebrafish model to study the renal involvement of HPS proteins in proteinuric kidney disease. Remarkably, knockdown of HPS genes in zebrafish causes glomerular injury with edema, proteinuria and structural changes of the glomerular filtration barrier. Moreover, reduced expression of HPS proteins in zebrafish recapitulates other important disease hallmarks, like hypopigmentation and accumulation of intracellular debris characteristic of lysosomal disorders. In conclusion, we present a valid zebrafish model that highlights the previously underestimated relevance of renal disease in HPS. This draws attention to the therapeutic options available to manage this component of the syndrome.


Disease Models, Animal , Hermanski-Pudlak Syndrome/genetics , Kidney/pathology , Zebrafish Proteins/genetics , Animals , Cell Line , Cells, Cultured , Endothelial Cells/metabolism , Endothelium, Vascular/cytology , Hermanski-Pudlak Syndrome/metabolism , Hermanski-Pudlak Syndrome/pathology , Humans , Kidney/metabolism , Lysosomes/metabolism , Lysosomes/pathology , Podocytes/metabolism , Zebrafish
6.
BMC Cancer ; 19(1): 429, 2019 May 09.
Article En | MEDLINE | ID: mdl-31072339

BACKGROUND: Despite rising incidence rates of colorectal malignancies, only a few prognostic tools have been implemented in proven clinical routine. Cell division and proliferation play a significant role in malignancies. In terms of colorectal cancer, the impact of proliferation associated proteins is controversially debated. The aim of our study was to examine the expression of topoisomerase II α and minichromosome maintenance protein 6 and to correlate these findings with the clinical data. METHODS: Tissue samples of 619 patients in total were stained using the antibodies Ki-S4 and Ki-MCM6 targeting topoisomerase II α as well as minichromosome maintenance protein 6. The median rate of proliferation was correlated with clinical and follow up data. RESULTS: The expression rate of minichromosome maintenance protein 6 is significantly higher than the proportion of topoisomerase II α in tumour cells (p < 0.001). A high expression of both proteins coincides with a beneficial outcome for the patient, indicating a favourable prognostic marker (p < 0.001 and p = 0.008). CONCLUSIONS: We have demonstrated that high expression rates of proliferative markers is linked to a beneficial patient outcome. According to the general opinion, a high expression rate correlates with a poor patient outcome. In this study, we were able to refute this assertion.


Biomarkers, Tumor/metabolism , Colorectal Neoplasms/pathology , DNA Topoisomerases, Type II/metabolism , Minichromosome Maintenance Complex Component 6/metabolism , Poly-ADP-Ribose Binding Proteins/metabolism , Aged , Cell Proliferation , Colon/pathology , Colon/surgery , Colorectal Neoplasms/mortality , Colorectal Neoplasms/surgery , Disease-Free Survival , Female , Humans , Male , Middle Aged , Prognosis , Rectum/pathology , Rectum/surgery , Retrospective Studies , Survival Analysis
7.
Internist (Berl) ; 60(1): 10-22, 2019 01.
Article De | MEDLINE | ID: mdl-30635666

BACKGROUND: Kidney involvement is a common complication in patients with plasma cell diseases. OBJECTIVE: This article outlines the spectrum of renal involvement in plasma cell dyscrasia and describes diagnostic and therapeutic measures to guide clinical management. MATERIAL AND METHODS: Evaluation and discussion of the current literature as well as existing guidelines and recommendations of professional societies. RESULTS: The clinical manifestations of renal involvement in plasma cell disorders are heterogeneous and range from acute cast nephropathy in multiple myeloma to rare forms of glomerulonephritis. The term monoclonal gammopathy of renal significance (MGRS) was introduced to describe kidney involvement caused by monoclonal gammopathy but without evidence for underlying malignancy. Light chain cast nephropathy is the most common renal manifestation in multiple myeloma, whereas monoclonal immunoglobulin deposition disease (MIDD) and renal light chain (AL) amyloidosis can be found in multiple myeloma and MGRS. Decisive is the extended hematological diagnostics in order to exclude the presence of a hematological neoplasm. The treatment of renal involvement in monoclonal gammopathies involves the reduction of the plasma cell clone with cytoreductive treatment. The reduction of the monoclonal protein in serum is prognostically relevant for the renal response to treatment. In the case of histological evidence of a light chain cast nephropathy, high cut-off dialysis is recommended to reduce the free light chains in serum. CONCLUSION: The spectrum of renal manifestations in plasma cell dyscrasia has been expanded, particularly since the introduction of the term MGRS. Diagnostic and therapeutic management remain an interdisciplinary challenge.


Kidney Diseases/diagnosis , Kidney Diseases/therapy , Kidney/pathology , Multiple Myeloma/pathology , Paraproteinemias/pathology , Plasma Cells/pathology , Glomerulonephritis , Humans , Immunoglobulin Light Chains/analysis , Kidney Diseases/etiology , Kidney Diseases/pathology , Multiple Myeloma/complications , Paraproteinemias/complications , Renal Dialysis , Sick Sinus Syndrome/congenital
9.
Zentralbl Chir ; 142(2): 180-188, 2017 Apr.
Article De | MEDLINE | ID: mdl-26562501

In cases of chronic renal insufficiency, successful kidney transplantation is the method of choice to restore patients' health, well-being and physical fitness. The interdisciplinary collaboration of nephrologists and transplant surgeons has always been a prerequisite for the successful pre-, peri- and post-transplant care of renal transplant patients. The same holds true for liver transplant patients. Here the nephrologist is often involved in cases requiring pre- or post-transplant dialysis as well as in decision making for combined liver-kidney transplantation. This review focuses on nephrological aspects in patient care before and after kidney and liver transplantation.


Interdisciplinary Communication , Intersectoral Collaboration , Kidney Transplantation , Liver Transplantation , Patient Care Team , Graft Rejection/diagnosis , Graft Rejection/therapy , Humans , Postoperative Complications/diagnosis , Postoperative Complications/therapy , Primary Graft Dysfunction/diagnosis , Primary Graft Dysfunction/therapy
10.
Internist (Berl) ; 57(1): 25-37, 2016 Jan.
Article De | MEDLINE | ID: mdl-26782281

In this paper, chronic rejections after transplantation of the lungs, heart, liver, and kidney are described. Chronic allograft dysfunction (CAD) plays an important role in all of these transplantations and has a significant influence on patient survival. The pathophysiological reasons for CAD varies greatly in the various organs.Chronic lung allograft dysfunction (CLAD) is the most important determinant of survival and quality of life after lung transplantation. Diagnosis is based on lung function, especially forced expiratory flow in 1 s (FEV1) decline. Prevention, early detection, and rapid treatment are extremely important. Azithromycin and extracorporeal photopheresis are commonly used for treatment because they usually positively influence the progression of lung remodeling.The expression for chronic rejection of the heart is cardiac allograft vasculopathy (CAV). Immunological and nonimmunological factors are important for its development. Due to limited therapeutic options, prevention is of utmost importance (administration of mTOR inhibitors and minimizing cardiovascular risk factors).The mid- and long-term survival rates after liver transplantation have hardly changed in recent decades, which is an indication of the difficulty in diagnosing chronic graft dysfunction. Chronic ductopenic rejection accounts for a small proportion of late graft dysfunction. Idiopathic posttransplant hepatitis and de novo autoimmune hepatitis are important in addition to recurrence of the underlying disease that led to transplantation.Chronic allograft nephropathy is the result of severe rejection which cumulates in increasing fibrosis with remodeling. The earliest possible diagnosis and therapy is currently the only option. Diagnosis is based on evidence of donor-specific antibodies and histological findings.


Graft Rejection/mortality , Heart Diseases/mortality , Kidney Diseases/mortality , Lung Diseases/mortality , Organ Transplantation/mortality , Postoperative Complications/mortality , Causality , Chronic Disease , Humans , Liver Diseases/mortality , Prevalence , Risk Factors , Survival Rate
12.
Z Rheumatol ; 74(4): 359-62, 2015 May.
Article De | MEDLINE | ID: mdl-25691108

CASE REPORT: We report the case of a patient with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis with involvement of the temporal artery, presenting with clinical manifestations of giant cell arteritis and temporal arteritis, such as temporal headache, jaw claudication, weight loss, night sweats and increased inflammatory parameters. The ultrasound scan showed a typical halo sign of the temporal artery. DIAGNOSTICS: In the case of further atypical organ symptoms, e.g. hematuria and proteinuria, detailed differential diagnostic investigations are essential to clarify the situation. Histological findings from the affected organs play a decisive role. CONCLUSION: An involvement of the temporal artery due to ANCA-associated vasculitis is extremely rare and may mimic giant cell arteritis. The exact diagnosis of ANCA-associated vasculitis is, however, important because this leads to a different approach concerning therapy and prognosis.


Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis , Cluster Headache/etiology , Fever of Unknown Origin/etiology , Intermittent Claudication/etiology , Jaw Diseases/etiology , Cluster Headache/diagnosis , Diagnosis, Differential , Fever of Unknown Origin/diagnosis , Humans , Intermittent Claudication/diagnosis , Jaw Diseases/diagnosis , Male , Middle Aged
13.
Clin Pharmacol Ther ; 95(4): 416-22, 2014 Apr.
Article En | MEDLINE | ID: mdl-24126681

Cytochrome P450 3A4 (CYP3A4) is a major drug-metabolizing enzyme that is widely investigated. So far, no homozygous inactive variant has been described. We report on a 19-year-old kidney transplant patient suffering from Alport syndrome, who experienced unexpected high tacrolimus plasma trough levels during immunosuppressant therapy. Because nonadherence, liver failure, or drug-drug interactions could be excluded, we hypothesized a diminished metabolism of the drug caused by mutations in the main detoxification enzyme, CYP3A4. Exome sequencing revealed a novel single-nucleotide polymorphism (c.802C>T) resulting in a premature stop codon in CYP3A4 exon 5. Accordingly, no CYP3A4 protein could be detected in kidney biopsy tissue, and there was lack of expression in HepG2 cells transiently transfected with the mutated CYP3A4. In addition, the patient harbored inactive CYP3A5*3, resulting in loss of function of the entire CYP3A locus, explaining the deteriorated tacrolimus clearance. This is, to our knowledge, the first case of a complete failure of CYP3A4 in humans.


Cytochrome P-450 CYP3A/genetics , Immunosuppressive Agents/pharmacokinetics , Kidney Transplantation , Tacrolimus/pharmacokinetics , Cytochrome P-450 CYP3A/metabolism , Genotype , Hep G2 Cells , Humans , Male , Mutation , Polymorphism, Single Nucleotide , Transfection , Young Adult
14.
Ophthalmologe ; 109(10): 1026-9, 2012 Oct.
Article De | MEDLINE | ID: mdl-22810150

We present a case of a bilateral vasoproliferative tumor of the retina in a young man. The first symptom was visual impairment due to vitreous hemorrhage. The right eye showed small tumors which were successfully treated by repeated cryocoagulation, photocoagulation and bevazicumab injection. The tumor in the left eye was larger and eventually led to a painful secondary glaucoma. After enucleation, this tumor was examined histologically and immunohistochemically. The clinical and histological differential diagnoses and therapeutic options are discussed.


Retinal Neoplasms/pathology , Retinal Neovascularization/pathology , Cryosurgery , Diagnosis, Differential , Eye Enucleation , Fluorescein Angiography , Glaucoma, Open-Angle/diagnosis , Glaucoma, Open-Angle/pathology , Glaucoma, Open-Angle/surgery , Humans , Laser Coagulation , Male , Ophthalmoscopes , Papilledema/diagnosis , Papilledema/pathology , Papilledema/surgery , Reoperation , Retina/pathology , Retinal Neoplasms/diagnosis , Retinal Neoplasms/surgery , Retinal Neovascularization/diagnosis , Retinal Neovascularization/surgery , Ultrasonography , Vitreous Hemorrhage/diagnosis , Vitreous Hemorrhage/pathology , Vitreous Hemorrhage/surgery , Young Adult
15.
Ophthalmologe ; 108(6): 570-4, 2011 Jun.
Article De | MEDLINE | ID: mdl-21431958

BACKGROUND: Histological findings of choroidal melanomas after proton beam irradiation have been reported for complicated cases after enucleation. We present specimens of a tumor after transretinal probe excision. PATIENT AND METHODS: One year after irradiation, the biopsy was examined histologically. RESULTS: The specimens showed pigmented, spindle-shaped cells staining positively for Melan-A and HMB-45. Ki-67 showed low proliferation. Caspase-3 staining was normal. CONCLUSIONS: The melanoma still contained vital and even single proliferating cells, but regressed afterwards without additional therapy.


Cell Survival/radiation effects , Choroid Neoplasms/radiotherapy , Melanoma/radiotherapy , Biopsy , Cell Proliferation , Choroid/pathology , Choroid/radiation effects , Choroid Neoplasms/pathology , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Ileal Neoplasms/pathology , Ileal Neoplasms/radiotherapy , Melanoma/pathology , Middle Aged , Neoplasm Staging , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/radiotherapy , Neuroendocrine Tumors/pathology , Neuroendocrine Tumors/radiotherapy , Ophthalmoscopes
17.
Arterioscler Thromb Vasc Biol ; 21(11): 1720-6, 2001 Nov.
Article En | MEDLINE | ID: mdl-11701456

Pathogenesis of in-stent restenosis remains poorly understood because information from human histopathologic studies is scarce. We used an improved saw-grinding and cutting method on methacrylate-embedded samples containing metal stents, which allows in situ hybridization and immunohistochemical analysis of in-stent restenosis. Twenty-one samples were collected 3 hours to 3 years after stenting from 6 patients aged 36 to 81 years. Except in very early samples collected within hours after the stent deployment, neovascularization was present in all segments studied. At advanced stages, extensive neovascularization was located mainly at the luminal side of the stent struts and was only rarely accompanied by inflammatory cells. The neovessels colocalized with vascular endothelial growth factor (VEGF)-A mRNA and protein expression as well as with iron deposits and oxidation-specific epitopes, which imply the presence of chronic oxidative stress. VEGF-A expression was detected in the same areas containing macrophages, endothelial cells, and, to a lesser extent, smooth muscle cells, which also showed platelet-derived growth factor-BB expression. We conclude that in-stent restenosis features neovascularization, VEGF-A and platelet-derived growth factor-BB expression, and iron deposition, which is most probably derived from microhemorrhages. These mechanisms may play an important role in the development of neointimal thickening and could provide useful targets for the prevention and treatment of in-stent restenosis.


Coronary Restenosis/metabolism , Endothelial Growth Factors/biosynthesis , Iron/metabolism , Neovascularization, Pathologic , Platelet-Derived Growth Factor/biosynthesis , Stents/adverse effects , Adult , Aged , Becaplermin , Coronary Restenosis/etiology , Coronary Restenosis/pathology , Coronary Thrombosis/pathology , Coronary Vessels/metabolism , Coronary Vessels/pathology , Endothelial Growth Factors/genetics , Endothelial Growth Factors/immunology , Epitopes/immunology , Female , Humans , Immunohistochemistry , In Situ Hybridization , Kinetics , Male , Methylmethacrylate/chemistry , Middle Aged , Oxidative Stress , Platelet-Derived Growth Factor/genetics , Platelet-Derived Growth Factor/immunology , Proto-Oncogene Proteins c-sis , RNA/biosynthesis , Transcription, Genetic , Vascular Endothelial Growth Factor A
18.
Am J Kidney Dis ; 38(3): 619-30, 2001 Sep.
Article En | MEDLINE | ID: mdl-11532696

The sites and mechanisms of the catabolism of atherogenic lipoprotein(a) (Lp(a)) are not well understood. Lp(a) is increased in patients with end-stage renal disease, suggesting a renal catabolism of Lp(a). To gain a better insight into renal handling of Lp(a), we established a heterologous rat model to study the renal catabolism of human Lp(a). Pure human Lp(a) was injected into Wistar rats, and animals were sacrificed at different time points (30 minutes to 24 hours). Intact Lp(a) was cleared from the circulation of injected rats with a half-life time of 14.5 hours. Strong intracellular immunostaining for apolipoprotein(a) (apo(a)) was observed in the cytoplasm of proximal tubular cells after 4, 8, and 24 hours. Apolipoprotein B (apoB) was colocalized with glomerular apo(a) 1 to 8 hours after Lp(a) injection, but renal capillaries and tubules remained negative. No relevant amounts of apo(a) fragments were found in the plasma of rats after injection of Lp(a). During all urine collection periods, apo(a) fragments with molecular weights of 50 to 160 kd were detected in the urine, however. Our results show that human Lp(a) injected into rats accumulates intracellularly in the rat kidney, and apo(a) fragments are excreted in the urine. The kidney apparently plays a major role in fragmentation of Lp(a). Despite the fact that rodents lack endogenous Lp(a), rats injected with human Lp(a) may provide a useful heterologous animal model to study the renal metabolism of Lp(a) further.


Kidney/metabolism , Lipoprotein(a)/metabolism , Peptide Fragments/metabolism , Animals , Apolipoproteins/administration & dosage , Apolipoproteins/metabolism , Apolipoproteins B/metabolism , Apoprotein(a) , Half-Life , Humans , Lipoprotein(a)/administration & dosage , Male , Models, Animal , Rats , Rats, Wistar
20.
Circulation ; 99(15): 2027-33, 1999 Apr 20.
Article En | MEDLINE | ID: mdl-10209008

BACKGROUND: Angiotensin II activates NAD(P)H-dependent oxidases via AT1-receptor stimulation, the most important vascular source of superoxide (O2*-). The AT1 receptor is upregulated in vitro by low-density lipoprotein. The present study was designed to test whether hypercholesterolemia is associated with increased NAD(P)H-dependent vascular O2*- production and whether AT1-receptor blockade may inhibit this oxidase and in parallel improve endothelial dysfunction. METHODS AND RESULTS: Vascular responses were determined by isometric tension studies, and relative rates of vascular O2*- production were determined by use of chemiluminescence with lucigenin, a cypridina luciferin analogue, and electron spin resonance studies. AT1-receptor mRNA was quantified by Northern analysis, and AT1-receptor density was measured by radioligand binding assays. Hypercholesterolemia was associated with impaired endothelium-dependent vasodilation and increased O2*- production in intact vessels. In vessel homogenates, we found a significant activation of NADH-driven O2*- production in both models of hyperlipidemia. Treatment of cholesterol-fed animals with the AT1-receptor antagonist Bay 10-6734 improved endothelial dysfunction, normalized vascular O2*- and NADH-oxidase activity, decreased macrophage infiltration, and reduced early plaque formation. In the setting of hypercholesterolemia, the aortic AT1 receptor mRNA was upregulated to 166+/-11%, accompanied by a comparable increase in AT1-receptor density. CONCLUSIONS: Hypercholesterolemia is associated with AT1-receptor upregulation, endothelial dysfunction, and increased NADH-dependent vascular O2*- production. The improvement of endothelial dysfunction, inhibition of the oxidase, and reduction of early plaque formation by an AT1-receptor antagonist suggests a crucial role of angiotensin II-mediated O2*- production in the early stage of atherosclerosis.


Angiotensin Receptor Antagonists , Arteriosclerosis/enzymology , Hypercholesterolemia/enzymology , Multienzyme Complexes/metabolism , NADH, NADPH Oxidoreductases/metabolism , Renin-Angiotensin System/physiology , Superoxides/metabolism , Acetylcholine/pharmacology , Acridines/analysis , Amlodipine/pharmacology , Amlodipine/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Animals , Antihypertensive Agents/pharmacology , Antihypertensive Agents/therapeutic use , Arteriosclerosis/etiology , Arteriosclerosis/physiopathology , Diet, Atherogenic , Dihydropyridines/pharmacology , Electron Spin Resonance Spectroscopy , Hypercholesterolemia/complications , Hypercholesterolemia/drug therapy , Hypercholesterolemia/genetics , Lipids/blood , Luminescent Measurements , Macrophages/pathology , Male , Phenylephrine/pharmacology , Rabbits , Receptor, Angiotensin, Type 1 , Receptor, Angiotensin, Type 2 , Receptors, Angiotensin/biosynthesis , Receptors, Angiotensin/physiology , Receptors, LDL/deficiency , Receptors, LDL/genetics , Tetrazoles/pharmacology , Up-Regulation , Vasoconstriction/drug effects , Vasoconstrictor Agents/pharmacology , Vasodilation/drug effects , Vasodilator Agents/pharmacology , Vasodilator Agents/therapeutic use
...